Literature DB >> 7962325

Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women.

R B Barnes1, R L Rosenfield, D A Ehrmann, J F Cara, L Cuttler, L L Levitsky, I M Rosenthal.   

Abstract

Women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency often have a polycystic ovary-like syndrome, consisting of hyperandrogynism, infertility, menstrual irregularities, and elevated LH levels. This is generally considered secondary to poor control of the congenital adrenal hyperplasia. However, our experience led us to suspect that ovarian hyperandrogenism occurs even when congenital adrenal hyperplasia is well controlled on glucocorticoid therapy. Therefore, we tested the hypothesis that congenital adrenal virilizing disorders result in ovarian hyperandrogenism. We studied eight women with congenital adrenal virilizing disorders, seven with well controlled classic 21-hydroxylase deficiency and one with congenital virilizing adrenal carcinoma removed at 1.7 yr of age. We also studied six women with late-onset 21-hydroxylase deficiency, without signs of congenital virilization. An ovarian source of androgens was assessed after suppressing adrenal function with dexamethasone and then testing pituitary-ovarian function by a GnRH agonist (nafarelin) test. Five women with congenital adrenal virilizing disorders (four with classic 21-hydroxylase deficiency and one with congenital virilizing adrenal carcinoma) and one women with late-onset 21-hydroxylase deficiency had ovarian hyperandrogenism as determined by subnormal suppression of free testosterone after dexamethasone and/or by increased 17-hydroxyprogesterone response to nafarelin while on dexamethasone. All women with congenital adrenal virilization and ovarian hyperandrogenism had elevated LH levels after dexamethasone or elevated early LH response to nafarelin, which suggests that LH excess is the cause of their ovarian hyperandrogenism. This was not the case for the late-onset 21-hydroxylase-deficient woman. Our data are compatible with the hypothesis that congenital adrenal virilization programs the hypothalamic-pituitary axis for hypersecretion of LH at puberty. This is postulated to frequently cause ovarian hyperandrogenism even when adrenal androgen excess is subsequently controlled by glucocorticoid therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7962325     DOI: 10.1210/jcem.79.5.7962325

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  90 in total

Review 1.  Developmental Programming, a Pathway to Disease.

Authors:  Vasantha Padmanabhan; Rodolfo C Cardoso; Muraly Puttabyatappa
Journal:  Endocrinology       Date:  2016-02-09       Impact factor: 4.736

2.  Anogenital distance in newborn daughters of women with polycystic ovary syndrome indicates fetal testosterone exposure.

Authors:  E S Barrett; K M Hoeger; S Sathyanarayana; D H Abbott; J B Redmon; R H N Nguyen; S H Swan
Journal:  J Dev Orig Health Dis       Date:  2018-01-09       Impact factor: 2.401

Review 3.  Role of stress and sympathetic innervation in the development of polycystic ovary syndrome.

Authors:  Monika Greiner; Alfonso Paredes; Verónica Araya; Hernán E Lara
Journal:  Endocrine       Date:  2005-12       Impact factor: 3.633

Review 4.  Developmental Programming of Ovarian Functions and Dysfunctions.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  Vitam Horm       Date:  2018-02-22       Impact factor: 3.421

Review 5.  Mechanisms of intergenerational transmission of polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Luis R Hoyos; Gregorio D Chazenbalk; Rajanigandha Naik; Vasantha Padmanabhan; David H Abbott
Journal:  Reproduction       Date:  2020-01       Impact factor: 3.906

6.  Developmental Programming: Prenatal and Postnatal Androgen Antagonist and Insulin Sensitizer Interventions Prevent Advancement of Puberty and Improve LH Surge Dynamics in Prenatal Testosterone-Treated Sheep.

Authors:  Vasantha Padmanabhan; Almudena Veiga-Lopez; Carol Herkimer; Bachir Abi Salloum; Jacob Moeller; Evan Beckett; Rohit Sreedharan
Journal:  Endocrinology       Date:  2015-04-28       Impact factor: 4.736

Review 7.  The role of TGF-β in polycystic ovary syndrome.

Authors:  Nazia Raja-Khan; Margrit Urbanek; Raymond J Rodgers; Richard S Legro
Journal:  Reprod Sci       Date:  2013-04-12       Impact factor: 3.060

8.  Endocrine antecedents of polycystic ovary syndrome in fetal and infant prenatally androgenized female rhesus monkeys.

Authors:  David H Abbott; Deborah K Barnett; Jon E Levine; Vasantha Padmanabhan; Daniel A Dumesic; Steve Jacoris; Alice F Tarantal
Journal:  Biol Reprod       Date:  2008-04-02       Impact factor: 4.285

9.  Associations of birthweight and gestational age with reproductive and metabolic phenotypes in women with polycystic ovarian syndrome and their first-degree relatives.

Authors:  Richard S Legro; Rebecca L Roller; William C Dodson; Christina M Stetter; Allen R Kunselman; Andrea Dunaif
Journal:  J Clin Endocrinol Metab       Date:  2009-12-04       Impact factor: 5.958

10.  Developmental programming: impact of prenatal testosterone excess and postnatal weight gain on insulin sensitivity index and transfer of traits to offspring of overweight females.

Authors:  V Padmanabhan; A Veiga-Lopez; D H Abbott; S E Recabarren; C Herkimer
Journal:  Endocrinology       Date:  2009-12-04       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.